These NTRK mutations are different from the acquired mutations described as a resistance mechanism to TRK inhibitors; as expected, the known acquired NTRK mutations that confer resistance were not observed in any of the 13 467 treatment-naïve tumours [119]. This evidence concerns the gene NTRK1 and neoplasm.